In 2022, the FDA approved the combination of trametinib and dabrafenib (a BRAF inhibitor) in a tumor-agnostic fashion for the treatment of patients ≥ 6 years of age with unresectable/metastatic BRAF V600E-mutant solid tumors that have progressed after prior treatment and have no satisfactory alternative. The gene discussed is BRAF; the disease is neoplasm.